



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel .: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2020-21
January 27, 2021

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

BSE CODE – 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Bandra - Kurla
Complex, Bandra (E), Mumbai – 400051

NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Press Release for December 2020

Please find attached herewith press release on the Financial Results for the quarter ended December 31, 2020.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M.No.: A54527




Aarti Drugs Ltd.

Press Release

Aarti Drugs Limited: Corporate Updates

Mumbai, January 27, 2021



*All numbers are on consolidated basis & EBITDA is before exceptional items

(Rs. in Crores except share data)

Particulars	Standalone Quarter ended		Consolidated Quarter ended	
	31-Dec-2020	31-Dec-2019	31-Dec-2020	31-Dec-2019
Revenue from Operations	472.10	415.61	530.25	473.51
EBITDA*	101.88	59.43	107.76	67.73
PBT*	84.93	39.50	90.14	46.98
PAT	64.66	26.75	68.03	27.78
EPS (Basic and Diluted) Rs.	6.94	2.87	7.30	2.98

* EBITDA & PBT excludes exceptional Items but includes other income



Aarti Drugs Ltd.

In the December'2020 quarter, the Company recorded consolidated quarterly revenue from operations of Rs.530.25 Crores with year-on-year increase of 11.98%. API segment contributed approximately 87% and formulation around 13% of the total consolidated revenues. Domestic sales of the API segment grew by approximately 13.50% and exports by 13.77%. Around 66% of this growth in the API segment was driven by volume growth due to good demand across multiple therapies. Formulation segment revenues grew by around 5.21% on a year-on-year basis.

Consolidated EBITDA for the quarter ended December'2020 is Rs.107.76 Crores, up by 59.11% and consolidated profit after tax for the quarter ended December'2020 is Rs.68.03 Crores, up by 144.88% on a year-on-year basis. Consolidated EBITDA margin improved from last year to 20.25%. Debt/Equity ratio of the Company reduced further down to 0.39 as of December'2020 on a consolidated basis due to strong internal accruals. This puts the Company in a good position for raising long term debt in addition to strong internal accruals to finance upcoming projects.

Recently expanded anti-inflammatory capacity is contributing to growth. The company is also in the process of commissioning new anti-diabetic production line for new product launch. In addition, brown field expansion of one its anti-biotic product would also be completed in near future. Topline growth would be further supported by good traction in the formulation exports. The company is also ramping up its R&D facilities to support future growth & innovations. In efforts to support environment, the Company has recently converted two more of its facilities to zero organic effluent discharge category and has already applied to the pollution board for the same.

FOR AARTI DRUGS LIMITED



ADHISH P. PATIL

CHIEF FINANCIAL OFFICER

About Us:



**THE CHEMISTRY
OF SUSTAINED
RELATIONSHIPS**



Aarti Drugs Limited was established in the year 1984 and is a part of \$1000 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited. Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.